Insmed freezes Brinsupri’s HS programme on Phase II failure
Insmed is putting a stop to the development of Brinsupri (brensocatib) in hidradenitis suppurativa (HS) after the drug failed to…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Tempus’ automated alerts boost patient outcomes in valvular heart disease
Tempus and Medtronic have uncovered the potential of artificial intelligence (AI)-driven electronic clinician notifications (ECNs) in improving outcomes and supporting…
-
EMA backs virtual animal control as preclinical NAM amid animal testing phaseout
The European Medicines Agency (EMA) has issued a fresh blueprint on the use of new approach methodologies (NAMs) amid its…
-
MoonLake’s lead asset shows durability in late-stage HS studies
MoonLake Immunotherapeutics’ targeted therapy, sonelokimab, has offered long-term disease-modifying and quality of life (QoL)-boosting benefits during two Phase III hidradenitis…
-
J&J’s Spravato touts durable anti-depressant benefits in real-world study
A real-world study has revealed the long-term impact of Johnson & Johnson’s (J&J) Spravato (esketamine) in treatment-resistant depression (TRD), which…
-
AstraZeneca’s novel COPD drug secures double win in Phase III
AstraZeneca’s first-in-class biologic, tozorakimab, has posted a double Phase III win in chronic obstructive pulmonary disease (COPD), which analysts say could position the…
-
Oral vaccine cuts up to 80.6% of E.coli-triggered diarrhoea cases
A novel oral vaccine, ETVAX, has demonstrated its potential to reduce paediatric cases of moderate-to-severe enterotoxigenic E. coli (ETEC)-triggered diarrhoea…
-
Ocugen’s GA gene therapy garners mixed sentiments on 12-month Phase II readout
Ocugen has secured a win for its one-time gene therapy, OCU410, in geographic atrophy (GA), though the recent data is…
-
Insmed eyes Arikayce label expansion on Phase IIIb lung disease success
Insmed is looking to expand the role of its inhaled Mycobacterium avium complex (MAC) lung disease therapy, Arikayce (amikacin), following the…
-
Roche drops Phase III plans for emugrobart in two muscle wasting diseases
Roche has halted plans to progress its anti-myostatin antibody, emugrobart, to Phase III trials in spinal muscular atrophy (SMA) and…